NBIX vs SABR · P/E 45, rev $1.77B vs rev $1.47B
Neurocrine Biosciences Inc (NBIX) versus Sabre Corpo (SABR) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Sabre Corpo (SABR) is a software - infrastructure company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported SABR revenue for 2026-06-30 was $1.47B. Net income was -$28.1M. Revenue was up 93.6% from 2026-03-31 to 2026-06-30. SABR currently screens at market cap $735.3M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SABR currently screens at market cap $735.3M.
Not investment advice. Open the NBIX and SABR stock pages for the full models.
Not investment advice.